PHASE II
Clinical trials for PHASE II explained in plain language.
Never miss a new study
Get alerted when new PHASE II trials appear
Sign up with your email to follow new studies for PHASE II, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new immunotherapy combo tame aggressive appendiceal cancer?
Disease control Not yet recruitingThis phase II trial is testing whether combining the experimental immunotherapy drug ivonescimab with chemotherapy (paclitaxel) delivered directly into the abdomen can safely and effectively treat people with high-grade metastatic appendiceal adenocarcinoma that cannot be removed…
Matched conditions: PHASE II
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat adrenal tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether the drug ivonescimab can help control advanced or metastatic adrenal cancers, specifically adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), that have not responded to prior treatment. About 20 adults with these rare c…
Matched conditions: PHASE II
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining an experimental drug called S-531011 with a precise radiation technique known as RadScopal can help control metastatic colorectal cancer that has not responded to prior treatments. The study enrolls about 30 adults with advanced dis…
Matched conditions: PHASE II
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug imetelstat targets rare blood cancer in phase 2 trial
Disease control Not yet recruitingThis Phase 2 trial tests the drug imetelstat in 30 adults with myelodysplastic/myeloproliferative neoplasms (MDS/MPN), a rare blood cancer. The goal is to see if imetelstat can help control the disease and to check for side effects. Participants receive the drug by IV, and the st…
Matched conditions: PHASE II
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare kidney cancer: drug trial targets tough tumors
Disease control Not yet recruitingThis study tests a drug called sacituzumab tirumotecan in 20 people with a rare and aggressive kidney cancer (SMARCB1-deficient renal medullary carcinoma) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink or control the cancer. Resear…
Matched conditions: PHASE II
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC